Benzinga's Weekend M&A Chatter

The following are the M&A deals, rumors and chatter circulating on Wall Street for Friday November 27 through Sunday November 29, 2015: Consortium Submits Preliminary Non-binding Proposal to Acquire iKang for $22/ADS The Offer:
Jiangsu Sanyou Group Co Ltd, Meinian Onehealth Healthcare (Group) Co., Ltd, Shenzhen Ping An Decheng Investment Co., Ltd., Taiping Guofa (Suzhou) Capital Management Co., Ltd., Huatai Ruilian Fund Management Co., Ltd., Sequoia China Investment Management LLP and Cathay Capital Private Equity SAS are part of a consortium, which has submitted a preliminary non-binding proposal to acquire, iKang Healthcare Group, Inc. KANG for $22 per ADS. iKang had announced receipt an offer of $17.80 per ADS on August 31, 2015 from founder, Chairman and CEO Ligang Zhang. iKang shares fell 1.41% Friday, closing at $16.77. Hearing Unconfirmed Takeover Chatter Cyclacel Could be Takeover Target for Martin Shkreli and Kalobios The Rumor:
Shares of Cyclacel Pharmaceuticals, Inc. CYCC surged higher Friday, on unconfirmed market chatter that the company might be a takeover target for Martin Shkreli and Kalabios Pharmaceuticals, Inc. KBIO. A spokesperson for Cyclacel was not available for comment. Cyclacel rose 47.83% Friday, closing at $1.02. Sanofi Said to be Considering Sale of Merial Animal Health Unit The Rumor:
Sanofi SNY is said to be preparing a sale of its Merial animal health unit, and is working with Lazard on the deal, according to sources as reported by Reuters on Friday. The Merial unit could be valued at up to $12.7 billion, the sources said. Sanofi and Lazard did not provide comment to Reuters. Sanofi closed at $44.31 Friday, and traded as high as $45.21 after-hours.